One engine combining proprietary biology, validated data, AI and high-throughput automation to redefine the speed and scale of antibody discovery.
Fully Human Antibody
Platform
AI Selection Model Trained
on 1B+ Sequences
In Vitro
& In Vivo
Validation
To build a scalable fully human antibody library, our proprietary RenMice® suite and target knockout strategy break immune tolerance to unlock the full antibody repertoire, enabling broad coverage of conserved, hard-to-hit epitopes. Furthermore, in vivo negative selection guarantees high target specificity, superior safety and downstream developability.
TAA Projects
Available for easy plug-and-play
Hu-VHH Projects
TFR1, CD98, 4-1BB, CD3, etc.
GPCR Projects
CCR8, GPRC5D, LGR5, CCR2 etc..
Dual-TAA bsADCs
Ready for out-licensing
TCR mimic Projects
GP100, WT1, KRAS, etc..
Autoimmune Projects
OX40, CD40, TNFSF15, etc..
Our proprietary intelligence layer accelerates discovery workflows by combining massive biological datasets with high-throughput NGS and advanced machine learning models.
High hit success, functional relevance
Trained on large-scale, validated fully human antibody data
De-risked, ready-to-scale candidates
Wet-lab results continuously refine AI models
Biology-Grounded AI Engine
From 10 MILLION possibilities to 20-100 diverse, high-quality candidates - powered by our proprietary biology and AI.
Our RenMice® fully human antibody mice, combined with our Target Knockout (KO) strategy, generate antibodies against novel and conserved epitopes that other platforms miss.
Plasma-cell NGS (Next-Generation Sequencing) captures the full antibody-rich repertoire.
Our proprietary AI analyzes billions of real-world binding data to predict binding, cross-reactivity and developability, selecting the top candidates with the highest potential.
The final Al-selected candidates are synthesized and tested in the lab for top binders and functional performance.
Superior Candidates, Faster Decision
High-affinity, developable antibodies with greater confidence.
Evaluated using SPR-based affinity screening across discovery campaigns.
Median Hit Rate
IQR:68% - 90%Maximum Hit Rate
Across CampaignsNGS & AI Workflow vs. Conventional Screening
Built for Difficult Targets
Overcome challenging targets where traditional screening falls short—In HCAb discovery campaigns, AI-driven selection expands hit discovery by 20× and enriches high-affinity candidates.
Target Success Rate
Target yield qualified antibody hits
Binding Hit Rate
AI-prioritized + synthesized antibody bind by flow cytometry
High-Affinity Rate
Experimentally validated KD ≤ 10⁻⁸ M
End-to-end manufacturing for speed, consistency, and scalability utilizing a 100% hands-free robotic workflow from plasmid to purified therapeutic protein production.
RenSuper™ combines validated biology, first-in-class closed-loop intelligence, and automated manufacturing to bring the industry's most reliable antibody discovery online.